BioCryst Pharmaceuticals BCRX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's total equity?
- BioCryst Pharmaceuticals (BCRX) reported total equity of -$553.84M in Q1 2026.
- How has BioCryst Pharmaceuticals's total equity changed year-over-year?
- BioCryst Pharmaceuticals's total equity decreased by 22.6% year-over-year, from -$451.93M to -$553.84M.
- What is the long-term trend for BioCryst Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's total equity has grown at a 44.0% compound annual growth rate (CAGR), from -$19.26M to -$119.15M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.